All In Biotech

Drug Trial Radar · NCT04261712

A Study to Evaluate the Long-Term Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Advance)

An Open Label, Long-term Extension Study to Evaluate the Safety and Efficacy of CRN00808 in Subjects With Acromegaly (ACROBAT Advance)

Last checked: Nov 20, 2026Latest source record: Jul 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

43

Actual

Start

Jan 29, 2020

Primary completion

Jun 30, 2026

Study completion Jun 30, 2026

Sponsor

Lead sponsor
Crinetics Pharmaceuticals Inc.Industry
Sponsor type
Industry
First posted
Feb 10, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A phase 2, open label, long-term extension study designed to evaluate the safety and efficacy of paltusotine (formerly CRN00808; an oral selective nonpeptide somatostatin receptor type 2 biased agonist) in subjects with acromegaly.

Conditions

  • Acromegaly

Interventions

  • PaltusotineDrug

    Paltusotine, once daily by mouth

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of treatment-emergent adverse events (TEAEs) throughout the studyTime frame: Week 316

Locations

22 sites in 7 countries. Site status is shown where the registry gives one.

  • Crinetics Study Site

    Los Angeles, California

  • Crinetics Study Site

    Chicago, Illinois

  • Crinetics Study Site

    Boston, Massachusetts

  • Crinetics Study Site

    Columbus, Ohio

  • Crinetics Study Site

    Pittsburgh, Pennsylvania

  • Crinetics Study Site

    Pittsburgh, Pennsylvania

  • Crinetics Study Site

    Dallas, Texas

  • Crinetics Study Site

    Rio de Janeiro, Brazil

  • Crinetics Study Site

    Rio de Janeiro, Brazil

  • Crinetics Study Site

    São Paulo, Brazil

  • Crinetics Study Site

    Curitiba, Paraná, Brazil

  • Crinetics Study Site

    München, Germany

  • Crinetics Study Site

    Athens, Greece

  • Crinetics Study Site 1

    Athens, Greece

  • Crinetics Study Site 2

    Athens, Greece

  • Crinetics Study Site

    Thessaloniki, Greece

  • Crinetics Study Site

    Budapest, Hungary

  • Crinetics Study Site

    Budapest, Hungary

  • Crinetics Study Site

    Pécs, Hungary

  • Crinetics Study Site

    Belgrade, Serbia

  • Crinetics Study Site

    Coventry, United Kingdom

  • Crinetics Study Site

    Leeds, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.